Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center explains the potential impact of abatacept, which is now FDA-approved to prevent acute graft-versus-host disease (GvHD) in patients 2 years of age or older receiving a hematopoietic stem cell transplant from a matched or single-HLA-mismatched unrelated donor.
1st Pediatric Drug Approved For Prevention Of Graft-Versus-Host Disease | Contact Us
Contact the Hematopoietic (Stem) Cell Transplant Program
888-PEDI-ONC (888-733-4662)
Fax
617-632-1990
International
+1-617-355-5209